Published in J Neurosci on December 17, 2008
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A (2009) 2.68
Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells. Neuropsychopharmacology (2010) 1.29
Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov (2009) 1.22
Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade. Psychopharmacology (Berl) (2009) 1.19
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry (2011) 1.18
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
A fatty gut feeling. Trends Endocrinol Metab (2013) 1.10
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther (2011) 1.08
Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors. Biol Psychiatry (2010) 1.05
Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. Neuropsychopharmacology (2012) 1.01
Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One (2012) 0.97
Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors. Addict Biol (2010) 0.97
Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence. Curr Drug Targets (2013) 0.94
Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse. Neuropsychopharmacology (2015) 0.93
Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther (2013) 0.92
Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology (2012) 0.91
The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence. Life Sci (2012) 0.89
Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc Lond B Biol Sci (2012) 0.89
Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice. J Neurosci (2014) 0.88
Sex-specific tonic 2-arachidonoylglycerol signaling at inhibitory inputs onto dopamine neurons of Lister Hooded rats. Front Integr Neurosci (2013) 0.87
The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol (2012) 0.87
Animal models of cannabinoid reward. Br J Pharmacol (2010) 0.84
PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings. PLoS One (2013) 0.84
Endocannabinoids and the processing of value-related signals. Front Pharmacol (2012) 0.83
Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARα agonist fenofibrate in a rat model. Psychopharmacology (Berl) (2010) 0.82
Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model. J Epilepsy Res (2014) 0.81
AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. J Psychopharmacol (2013) 0.81
The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms. Br J Pharmacol (2013) 0.81
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat (2009) 0.81
The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area. Neuropsychopharmacology (2012) 0.81
Role of the satiety factor oleoylethanolamide in alcoholism. Addict Biol (2015) 0.81
Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats. Int J Neuropsychopharmacol (2014) 0.79
New insights on endocannabinoid transmission in psychomotor disorders. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.79
Interference with acute nausea and anticipatory nausea in rats by fatty acid amide hydrolase (FAAH) inhibition through a PPARα and CB1 receptor mechanism, respectively: a double dissociation. Psychopharmacology (Berl) (2015) 0.79
Oleoylethanolamide: a novel potential pharmacological alternative to cannabinoid antagonists for the control of appetite. Biomed Res Int (2014) 0.78
Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro. Lipids Health Dis (2012) 0.78
Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia. Front Psychiatry (2012) 0.78
An update on PPAR activation by cannabinoids. Br J Pharmacol (2016) 0.78
Dietary triacylglycerols with palmitic acid in the sn-2 position modulate levels of N-acylethanolamides in rat tissues. PLoS One (2015) 0.77
Maternal Immune Activation Disrupts Dopamine System in the Offspring. Int J Neuropsychopharmacol (2016) 0.76
Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. Psychopharmacology (Berl) (2016) 0.75
In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence. Neuropharmacology (2017) 0.75
The Epac-Phospholipase Cε Pathway Regulates Endocannabinoid Signaling and Cocaine-Induced Disinhibition of Ventral Tegmental Area Dopamine Neurons. J Neurosci (2017) 0.75
The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats. Neuropharmacology (2017) 0.75
Putative Epigenetic Involvement of the Endocannabinoid System in Anxiety- and Depression-Related Behaviors Caused by Nicotine as a Stressor. PLoS One (2016) 0.75
Fenofibrate Administration Reduces Alcohol and Saccharin Intake in Rats: Possible Effects at Peripheral and Central Levels. Front Behav Neurosci (2017) 0.75
Interactions between nicotine and drugs of abuse: a review of preclinical findings. Am J Drug Alcohol Abuse (2016) 0.75
Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats. Psychopharmacology (Berl) (2016) 0.75
Dopamine, learning and motivation. Nat Rev Neurosci (2004) 11.97
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A (1988) 11.96
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
The mechanisms of action of PPARs. Annu Rev Med (2002) 6.71
Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science (2004) 5.62
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci (1984) 4.52
Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol (1992) 3.98
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--1. Identification and characterization. Neuroscience (1983) 3.09
Nicotine activates and desensitizes midbrain dopamine neurons. Nature (1997) 3.02
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A (2005) 2.96
An anorexic lipid mediator regulated by feeding. Nature (2001) 2.94
Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci (2008) 2.87
Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience (2004) 2.84
Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci (2001) 2.69
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev (2006) 2.25
Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J (2006) 2.01
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther (2007) 1.96
Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci (2007) 1.95
Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci (2004) 1.85
Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther (2004) 1.83
SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol (2002) 1.75
The endocannabinoid system in brain reward processes. Br J Pharmacol (2008) 1.71
Structural basis for lipid modulation of nicotinic acetylcholine receptor function. Brain Res Brain Res Rev (2004) 1.57
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol (2001) 1.45
Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport (2004) 1.37
Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem (2006) 1.35
Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol (2007) 1.32
Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J Neurosci (2005) 1.30
Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther (2008) 1.29
Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol (1987) 1.26
Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther (2007) 1.18
Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol Pharmacol (2005) 1.16
Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol (2008) 1.15
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology (2008) 1.14
The neurobiology of tobacco addiction. Trends Pharmacol Sci (1991) 1.14
Cannabinoids and PPARalpha signalling. Biochem Soc Trans (2006) 1.13
Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl) (2005) 1.12
Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical- and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology (2005) 1.10
The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav (2005) 1.09
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain (2007) 1.09
Rapid upregulation of alpha7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J Neurosci (2005) 1.08
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev (2007) 1.05
FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci (2008) 1.04
The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol (2007) 1.02
The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology (2007) 1.00
The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol (2007) 1.00
Excitatory and inhibitory responses of dopamine neurons in the ventral tegmental area to nicotine. Synapse (2002) 1.00
Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture. Biochim Biophys Acta (1995) 0.99
The endogenous cannabinoid anandamide inhibits alpha7 nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther (2003) 0.90
Bovine serum albumin enhances nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. J Neurochem (2002) 0.88
Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. J Neurochem (2008) 0.87
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med (2009) 2.82
Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci (2006) 2.29
Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology (2012) 2.28
Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) (2004) 2.07
Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem (2003) 1.96
Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis (2008) 1.96
Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology (2012) 1.91
Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci (2004) 1.85
Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther (2004) 1.83
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data. Psychopharmacology (Berl) (2003) 1.66
Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal Chem (2004) 1.63
Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) (2003) 1.59
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 1.54
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci (2008) 1.52
Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci (2004) 1.52
Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl) (2004) 1.48
Would you refer this patient to hospice? An evaluation of tools for determining life expectancy in end-stage dementia. J Palliat Med (2007) 1.44
The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology (2005) 1.43
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Braking dopamine systems: a new GABA master structure for mesolimbic and nigrostriatal functions. J Neurosci (2012) 1.42
Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology (2003) 1.41
Second-order schedules of drug self-administration in animals. Psychopharmacology (Berl) (2002) 1.39
Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport (2004) 1.37
Environmental enrichment reduces cocaine seeking and reinstatement induced by cues and stress but not by cocaine. Neuropsychopharmacology (2009) 1.35
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem (2006) 1.35
Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) (2005) 1.35
Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol (2009) 1.31
Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci U S A (2002) 1.30
Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem (2008) 1.30
High reinforcing efficacy of nicotine in non-human primates. PLoS One (2007) 1.29
Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci (2011) 1.29
Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther (2008) 1.29
Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells. Neuropsychopharmacology (2010) 1.29
Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology (2007) 1.28
Two brain sites for cannabinoid reward. J Neurosci (2006) 1.27
Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord (2004) 1.27
Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. J Neurochem (2004) 1.27
Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction (2007) 1.27
Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology (2005) 1.24
Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc (2006) 1.24
Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacology (Berl) (2004) 1.22
Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS One (2010) 1.22
Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. J Pharmacol Exp Ther (2009) 1.21
Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists. PLoS One (2011) 1.20
The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci (2005) 1.20
Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci (2002) 1.20
Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry (2004) 1.20
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry (2011) 1.18
Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology (2005) 1.18
The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl) (2003) 1.16
Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem (2009) 1.16
Oxytocin injected into the ventral tegmental area induces penile erection and increases extracellular dopamine in the nucleus accumbens and paraventricular nucleus of the hypothalamus of male rats. Eur J Neurosci (2007) 1.16
Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol (2008) 1.15
Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology (2008) 1.15
Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem (2004) 1.15
Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. Neuropsychopharmacology (2010) 1.15
Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology (2008) 1.15
Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats. Neuropsychopharmacology (2006) 1.14
Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse. Neuropsychopharmacology (2011) 1.14
Prior exposure to THC increases the addictive effects of nicotine in rats. Neuropsychopharmacology (2013) 1.14
Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J Mol Neurosci (2005) 1.12
Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis (2011) 1.12
Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists. Br J Pharmacol (2005) 1.10
CREB phosphorylation regulates striatal transcriptional responses in the self-administration model of methamphetamine addiction in the rat. Neurobiol Dis (2013) 1.10
Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology (2005) 1.09
Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions. Neuropharmacology (2004) 1.07
Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol (2011) 1.07
Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br J Pharmacol (2010) 1.07
Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release. Neuropsychopharmacology (2004) 1.07
Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res (2007) 1.07
Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. Int J Neuropsychopharmacol (2011) 1.06
Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology (2008) 1.06
Human cocaine-seeking behavior and its control by drug-associated stimuli in the laboratory. Neuropsychopharmacology (2005) 1.06
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One (2012) 1.05